Imikhiqizo

Ukwelashwa kwamangqamuzana ezincelisayo ngezidakamizwa ze-chemotherapeutic kungaholela ekuphazamisekeni kwamachibi e-nucleotide.Ukuqapha lokhu kuphazamiseka kumaseli wesimila akhulisiwe avela emithonjeni yabantu kuyasiza ekuhloleni umphumela wokwelashwa kwezidakamizwa kanye nokuqonda kangcono indlela yokusebenza kwale mithi.Kulolu cwaningo, amakilasi amathathu emithi ye-chemotherapeutic enezindlela ezihlukene zokwenza asetshenziswe ekuthuthukisweni kwamamodeli amaseli aphathwe izidakamizwa.Ukuhlaziywa kwe-metabolomics okuhlosiwe okusekelwe ku-LC kwama-nucleotide kumaseli weqembu lokulawula kanye neqembu eliphathwe izidakamizwa kwenziwa.Izindlela ezimbalwa zokucubungula idatha zahlanganiswa ukuze kukhonjwe ama-biomarker angaba khona ahlobene nesenzo sezidakamizwa, okuhlanganisa ukuhlaziywa kwendlela eyodwa yokuhlukahluka, ukuhlaziywa kwengxenye eyinhloko, namajika esici sokusebenza komamukeli.Ngokuthakazelisayo, amangqamuzana e-tumor kokubili iqembu elilawulayo kanye namaqembu aphathwe izidakamizwa angahlukaniswa komunye nomunye, futhi okuguquguqukayo okuningana kwaqashelwa njengama-biomarker anamandla, njenge-ATP, GMP, ne-UDP yama-antimetabolite agents, i-ATP, i-GMP, ne-CTP. kuma-ejenti alimaza i-DNA, kanye ne-GMP, i-ATP, i-UDP, ne-GDP yama-ejenti we-mitotic spindle.Ukuqinisekiswa okwengeziwe kwama-biomarker angaba khona kwenziwa kusetshenziswa ijika lesici sokusebenza komamukeli.Uma kucatshangelwa indawo yazo ehambisanayo ngaphansi kwejika, eyayinkulu kuno-0.9, kungaphethwa ngokuthi i-GMP ne-ATP zingama-biomarker angcono kakhulu angaba khona ezidakamizwa ezilimaza i-DNA, kanye ne-GMP, i-ATP, ne-UDP kwezinye izigaba ezimbili zezidakamizwa.Le ndlela elinganiselwe ye-nucleotide ayikwazi ukuhlukanisa ngokuphelele izindlela zemithi eyisishiyagalolunye, kodwa inikeza ubufakazi bokuqala bendima ye-pharmacemetabolomics ekuthuthukisweni kwangaphambili kwezidakamizwa okungenani.